Print view
 

Establishing a Global Vaccine-Development Fund

As the Ebola epidemic in West Africa continues, albeit at a much lower level than it reached in the spring, we still lack a vaccine that has been shown to be safe and effective.

 

Vaccine development is facing a crisis for three reasons: the complexity of the most challenging targets, which necessitates substantial investment of capital and human expertise; the diminishing numbers of vaccine manufacturers able to devote the necessary resources to research, development, and production; and the prevailing business model, which prioritizes the development of vaccines with a large market potential.

Much attention has appropriately been directed at major disease targets such as human immunodeficiency virus (HIV), tuberculosis, and malaria, for which organizations such as the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Wellcome Trust are providing considerable financial support. Similar attention has been devoted to the provision of currently licensed pediatric vaccines, which is supported by GAVI (formerly the Global Alliance for Vaccines and Immunization).

Thus, the pharmaceutical industry's enthusiasm for vaccine development has dropped well below the levels seen in the 1980s and 1990s. The ClinicalTrials.gov website shows that only a minority of trials of vaccines against new infectious disease targets are sponsored by major vaccine companies and that the total number of trials is not increasing.  

Read the full article at NEJM-website

 

Autor: Stanley A. Plotkin, M.D., Adel A.F. Mahmoud, M.D., Ph.D., and Jeremy Farrar, M.D., Ph.D. N Engl J Med 2015; 373:297-300July 23, 2015DOI: 10.1056/NEJMp   Quelle: The New England Journal of Medicine
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
Weitere News
Give us Access to Tigray to Find Missing Refugees — NRC Pleas
Where do UN Diplomats Hide During Politically-Sensitive Voting?
Q&A: Documenting COVID-19 Effect on Youth Sexual and Reproductive Health
COVID-19 Pandemic Shapes the Future World People Want
If Covid-19 is Primarily a ‘First World’ Virus, Why is the Global South in Lockdown?
We Need a Global Coordinated Effort to Secure Equal Access to Safe & Effective Vaccines
We Need a Global Coordinated Effort to Secure Equal Access to Safe & Effective Vaccines
Nothing to Learn from East Asia?
Covid-19: Lung Damage 'identified' in Study
Five Technologies That Will Transform Medicine In Post-Pandemic America
COVID-19 severity affected by proportion of antibodies targeting crucial viral protein
2020 New York Times Voices
WHO Coronavirus Disease (COVID-19) Dashboard
GHD|EMPHNET Launches Online Courses on Response to Public Emergencies
EUPHA strategy 2020-2025
150 years of the International Review of the Red Cross
Three Ways Forward in a Post Covid-19 World
Gender-sensitive Workplace Health Promotion: Why It Is Important and How It Can Be Implemented in Practice
COVID-19: the worst may be yet to come
Medicine shortages in the EU: causes and solutions
Coronavirus Makes Inequality a Public Health Issue
A ‘Cure’ for Ebola but Will it Stop the Outbreak if People Won’t Get Treatment?
The Role of Women’s Organisations in Crisis-Settings
CRA shortage is worsening while demand grows – a vicious circle which opens masses of job opportunities
Why Doctors Hate Their Computers
Junior hospital doctors
90–90–90 Treatment for All
Incident Management System
Incident Management System
An Economy for the 99%
European Virus Archive goes global

educational newsletter

 

European Public Health Association (EUPHA)Center of ExcellenceÖsterreichische Akademie der ÄrzteÄrzte der WeltÄrztekammer für WienAnästhesie in Entwicklungsländern e. V.AGEM - Arbeitsgemeinschaft Ethnologie und MedizinHilfswerk Austria